Organicell Regenerative Medicine, Inc. (OCEL) Financial Statements (2024 and earlier)

Company Profile

Business Address 3321 COLLEGE AVENUE
DAVIE, FL 33314
State of Incorp. NV
Fiscal Year End October 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

7/31/2023
MRQ
1/31/2023
MRQ
10/31/2022
10/31/2021
10/31/2020
10/31/2019
10/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,4233,75310959113343
Cash and cash equivalents1,4233,75310959113343
Receivables234191104292648
Inventory, net of allowances, customer advances and progress billings28124923514778 
Inventory28124923514778 
Prepaid expense215173707912115
Other undisclosed current assets 500     
Total current assets:2,6524,366517846358106
Noncurrent Assets
Operating lease, right-of-use asset    105 
Property, plant and equipment1,5441,6841,1133652636
Long-term investments and receivables      
Long-term investments      
Other undisclosed noncurrent assets1221513021855
Total noncurrent assets:1,6651,8341,41648826811
TOTAL ASSETS:4,3186,2011,9331,334626117
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,2682,3791,873766552477
Accrued liabilities8207581,5421,156853328
Other undisclosed accounts payable and accrued liabilities1,4481,621331(391)(300)149
Debt7144140233432380
Disposal group, including discontinued operation   126126126126
Due to related parties221221221221  
Other undisclosed current liabilities9291,3201,7661,194925349
Total current liabilities:3,4264,0634,1262,5402,0361,332
Noncurrent Liabilities
Long-term debt and lease obligation, including: 208220332186153 
Long-term debt, excluding current maturities 208 332   
Finance lease, liability  220 119 
Other undisclosed long-term debt and lease obligation     153 
Liabilities, other than long-term debt  29    
Operating lease, liability  29 67 
Other undisclosed noncurrent liabilities7 140(67)  
Total noncurrent liabilities:215249472186153 
Total liabilities:3,6414,3124,5992,7262,1891,332
Equity
Equity, attributable to parent, including:6771,889(2,666)(1,392)(1,563)(1,258)
Common stock1,4891,4791,132940503436
Additional paid in capital51,99650,93137,82726,53614,22012,854
Accumulated deficit(52,808)(50,521)(41,625)(28,868)(16,285)(14,548)
Other undisclosed equity, attributable to parent      (0)
Equity, attributable to noncontrolling interest      43
Total equity:6771,889(2,666)(1,392)(1,563)(1,215)
TOTAL LIABILITIES AND EQUITY:4,3186,2011,9331,334626117

Income Statement (P&L) ($ in thousands)

7/31/2023
TTM
1/31/2023
TTM
10/31/2022
10/31/2021
10/31/2020
10/31/2019
10/31/2018
Revenues5,9626,4915,5973,0561,702965
Gain on disposition of assets for financial service operations      821
Cost of revenue(709)(754)(548)(399)(301)(209)
Gross profit:5,2535,7375,0502,6571,401755
Operating expenses(14,631)(14,580)(17,794)(15,095)(3,178)(4,245)
Operating loss:(9,378)(8,843)(12,744)(12,438)(1,776)(3,490)
Nonoperating income
(Other Nonoperating income)
  25025338521
Interest and debt expense(419)(398) (178)(47)(228)
Other undisclosed income from continuing operations before equity method investments, income taxes250     
Loss from continuing operations before equity method investments, income taxes:(9,547)(8,992)(12,719)(12,583)(1,738)(3,697)
Other undisclosed income (loss) from continuing operations before income taxes5895(38)0 266
Loss from continuing operations before income taxes:(9,489)(8,897)(12,757)(12,583)(1,738)(3,431)
Income tax expense (benefit)   3,2153,168205(1,076)
Loss from continuing operations:(9,489)(8,897)(9,541)(9,415)(1,534)(4,507)
Loss before gain (loss) on sale of properties:(4,184)(9,541)(9,415)(1,534)(4,507)
Other undisclosed net income (loss)  (3,215)(3,168)(205)1,076
Net loss:(9,489)(8,897)(12,757)(12,583)(1,738)(3,431)
Net income (loss) attributable to noncontrolling interest     1(31)
Net loss available to common stockholders, diluted:(9,489)(8,897)(12,757)(12,583)(1,737)(3,462)

Comprehensive Income ($ in thousands)

7/31/2023
TTM
1/31/2023
TTM
10/31/2022
10/31/2021
10/31/2020
10/31/2019
10/31/2018
Net loss:(9,489)(8,897)(12,757)(12,583)(1,738)(3,431)
Comprehensive loss:(9,489)(8,897)(12,757)(12,583)(1,738)(3,431)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest     1(31)
Comprehensive loss, net of tax, attributable to parent:(9,489)(8,897)(12,757)(12,583)(1,737)(3,462)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: